Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

TG Therapeutics highlights potential of ublituximab for new indication

Aug. 28, 2012

Updated results from EMILIA study of trastuzumab emtansine

Aug. 27, 2012

Northwest Bio gains MHRA clearance for DCVax-L trial

Aug. 24, 2012

NICE publishes draft guidance on denosumab

Aug. 20, 2012

Lykera Biomed reports novel S100-P-directed antibodies

Aug. 20, 2012

New candidate immunotherapies divulged by UCB

Aug. 17, 2012

Biovest holds end-of-phase III meeting for BiovaxID

Aug. 16, 2012

Phase III study of OCV-C01 advances

Aug. 13, 2012

New ROR1-binding antibodies designed in California

Aug. 9, 2012

NIH designs recombinant oncolytic immunotoxins that may be given at high doses

Aug. 9, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...